Nurix Therapeutics Stock Price

-0.12 (-0.46%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Nurix Therapeutics Inc NRIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -0.46% 25.83 20:00:00
Open Price Low Price High Price Close Price Prev Close
25.90 25.48 27.55 25.83 25.95
Bid Price Ask Price Spread News
21.03 30.32 9.29 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,139 212,507 $ 26.24 $ 5,575,285 357,173 15.21 - 52.38
Last Trade Time Type Quantity Stock Price Currency
16:05:50 priorref 334 $ 25.83 USD

Nurix Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.15B 44.35M 31.04M $ 17.82M $ - -2.74 -7.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -21.40k 0.90%

more financials information »

Nurix Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NRIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.7828.0724.5526.06334,784-0.95-3.55%
1 Month28.7636.0424.5529.96327,999-2.93-10.19%
3 Months36.5147.8424.5533.20488,831-10.68-29.25%
6 Months32.1552.3824.5535.64389,446-6.32-19.66%
1 Year20.2552.3815.2133.30311,0625.5827.56%
3 Years20.2552.3815.2133.30311,0625.5827.56%
5 Years20.2552.3815.2133.30311,0625.5827.56%

Nurix Therapeutics Description

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Your Recent History
Nurix Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 06:47:26